Rheumatoid Arthritis specialists highlight importance of early aggressive treatment

Notes and media contacts

About Enbrel-
Enbrel is the first biologic therapy and the first human soluble tumour necrosis factor (TNF) receptor to be approved by the FDA and the European Medicines Evaluation Agency (EMEA) for the treatment of RA and is the first and only biologic therapy approved to treat juvenile chronic arthritis (JCA) and psoriatic arthritis. Enbrel is only fully human anti- TNF therapy approved to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis, and to reduce the signs and symptoms and inhibit the progression of structural damage in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be used alone or in combination.

About Wyeth-
Wyeth is a global leader and research based company in prescription pharmaceuticals, non-prescription consumer health care products and pharmaceuticals for animal health. Wyeth Pharmaceuticals products are sold in more than 140 countries, and its product portfolio includes innovative treatments across a wide range of therapeutic areas. Wyeth's worldwide resources include 52,000 employees, manufacturing facilities on four continents and a unique research and technology base encompassing small molecules, vaccines and biotechnology. With this depth of resources, Wyeth Pharmaceuticals will continue to lead the way in the development of novel therapies that address critical global health needs.
In 1963, Wyeth Pharmaceuticals opened an office in Egypt and two years later established itself in the Kingdom of Saudi Arabia and the UAE. It expanded its regional presence to the UAE in 1995. In 2004 Wyeth Pharmaceuticals established its Middle East & North Africa affiliate in Dubai, UAE.

For more information, please contact:
Mary Smiddy/Majid Wasi,
ASDA'A - a public relations consultancy,
Dubai, UAE,
Tel: +9714-3344550,
Fax: +9714-3344556,